BioAtla® develops novel cancer therapeutics that meet critical needs including improved safety and the treatment of previously undruggable cancers.Learn more
BioAtla® Enters Into Strategic License And Option Agreement With Pfizer For A New Class Of Antibody TherapeuticsLearn more
We are Hiring!
At BioAtla® we recognize that the success of our business depends on the excellence of our people, and are dedicated to recruiting exceptional talent for our team.Learn more
BioAtla® and Sinobioway Select First Program for Strategic Collaboration in China MarketLearn more
Conditionally Active Biologics™ (CAB’s)
BioAtla®’s revolutionary platform for developing conditionally active therapeutics yields antibodies (or other biologics) that can be activated or inactivated under defined physiological conditions.Learn more